After more than 10 months of coordination, repeated communication and public defense, we project "Diabetes Gene Diagnosis and Treatment" recently won the 2017 leader team in Zhoushan City, gained the government investment and is sought after by social capitals. Thus, we successfully complete the current round of investment plan.
Zhejiang Maida gene Technology Limited Company, has a registered capital of 10 million, the business area of more than 600 square meters. Professor Polychronakosas the chief scientist of our company, is the academician from Canadian Royal Society in both Academy of Sciences and Academy of Medical Sciences. He is also a professor in department of Human Genetics and Pediatrics and the top scientist of the Child Health and Human Development program in McGill University.
As a leader in the international diabetes genetics, Professor Polychronakos led the first major human genome-wide sequencing for type II diabetes mellitus susceptibility genes and the genome association study of type I diabetes mellitus, which was carried out by 14 research institutions from Canada, England and France. The results have been widely reported by internationally renowned media, such as the New York Times, American Newsweek, British Daily Telegraph, the Canadian national television etc. and he was hence evaluated as the pioneer of human genetics revolution that greatly influence human health.
The team has senior experts in project operation&marketing and Ph.Ds from Tsinghua University and the McGill University as technical team. The team has published more than 20 scientific papers in the top journals such as "science", "nature" and "nature genetics" , the key techniques also packed for five patents from US.
At present, the number of patients with diabetes in China is 114 million, the incidence rate has increased from 0.80% in 1980s to 11.6% in 2016, plus more than 100 million people with potential diabetes. The team focus on the development of genetic diagnosis technology and systematic a analysis in diabetes. Our technology has been generalized in a number of hospitals and carried out extensive cooperation, such as Anhui Medical University Affiliated Hospital , Fudan University Zhongshan Hospital, the international human genome variation and complex genome study of Fudan University, Shanghai Jiaotong University affiliated Shanghai Children's Hospital, Hangzhou Traditional Chinese Medicine Hospital, Xuzhou Children's Hospital, Xuzhou Maternal and Child Health Hospital, Nanjing Medical University etc.
The project signing ceremony was held at McGill University Health Center in Canada on May 26, 2017. Ms. Wang Wenxu, Director of Human Resources and Social Security Department of Zhejiang Province, Mr. Li Yong, Director of Zhejiang Provincial Foreign Experts Bureau attended the project signing activities and delivered speeches. More than 20 people from Canada, Zhejiang Province and Zhoushan City have attended the event.
Wang Wenzhang asked in detail about the company development strategy and the future plan, gave a high evaluation on the company's advanced development concept and world-class gene diagnosis &treatment technology , encourage the company to fully combine the market decisive role and government policy guidance, generalize the diabetes genetic diagnostic technology as soon as possible to promote the benefit of mankind.
In the meeting, top investor expressed great interests in this project, hope that through cooperation, the company can built a platform with "billion" or even " hundred billions" grade in the future."
Welcomed the major hospitals, medical schools to actively concern about and visit the company, open business negotiations and technical cooperation! In the future we will set up post-doctoral workstations in the company, welcome medical talents to join our company and start innovation and entrepreneurship.
The Montreal Chinese Academic Association will continue to maintain a low-key, pragmatic and open attitude, expected to launch a series of key projects in the field of key technological innovation and cultural innovation and provide children schooling help, talent accommodation and other aspects of supporting services.